Nature Reviews Clinical Oncology - Table of Contents alert Volume 10 Issue 8

TABLE OF CONTENTS
August 2013 Volume 10 Number 8
Impact Factor 15.031 *	In this issue Research Highlights News and Views Reviews Correspondence Also this month  Featured article: Liquid biopsy: monitoring cancer-genetics in the blood Emily Crowley, Federica Di Nicolantonio, Fotios Loupakis & Alberto Bardelli
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
New Impact Factor We are pleased to announce that the new impact factor for Nature Reviews Clinical Oncology is 15.031*. *2012 Journal Citation Reports® (Thomson Reuters, 2013)
RESEARCH HIGHLIGHTS Top From ASCO—gynaecological cancer: Advances in cervical cancer screening and treatment Published online: 18 June 2013 p425 | doi:10.1038/nrclinonc.2013.109 PDF Chemotherapy: Supplements—for better or worse? Published online: 18 June 2013 p426 | doi:10.1038/nrclinonc.2013.106 PDF Breast cancer: Stable breast cancer xenograft models Published online: 25 June 2013 p426 | doi:10.1038/nrclinonc.2013.111 PDF Liver cancer: SALL4—a cancer marker and target Published online: 25 June 2013 p426 | doi:10.1038/nrclinonc.2013.112 PDF Genetics: ZBTB7A suppresses castration-resistant prostate cancer Published online: 18 June 2013 p427 | doi:10.1038/nrclinonc.2013.107 PDF Urological cancer: Poorer prostate cancer outcomes in African American men Published online: 02 July 2013 p427 | doi:10.1038/nrclinonc.2013.114 PDF Liver cancer: Gut microbiota feeds obesity-induced liver cancer Published online: 09 July 2013 p428 | doi:10.1038/nrclinonc.2013.121 PDF IN BRIEF Genetics: Gene-expression profiling reveals subtypes of retinoblastoma | Basic research: Wnt signalling required for pancreatic carcinogenesis | Immunotherapy: Caution needed when engineering T cells and receptors | Basic research: Understanding why the naked mole rat is cancer resistant PDF Clinical Oncology JOBS of the week Senior Hematology / Oncology Faculty University of Maryland Greenebaum Cancer Center (UMGCC) Junior Research Group Leader (M / F) German Cancer Research Center (DKFZ) Post Doctoral Researcher The Ohio State University - Comprehensive Cancer Center Postdoctoral fellow position in the area of Computational Cancer Genomics University of Cologne Postdoctoral fellow University of California, San Francisco (UCSF) More Science jobs from Clinical Oncology EVENT 3rd Annual Oncology Biomarkers Congress 14.10.13 Manchester, UK More science events from
NEWS AND VIEWS		Top
Biological markers: Tailoring treatment and trials to prognosis David J. Kerr & Yuankai Shi Published online: 11 June 2013 p429 | doi:10.1038/nrclinonc.2013.97 As we learn more about the biology of cancer, we may be able to apply prognostic biomarkers to select patients at high risk or low risk of disease recurrence or progression. This will allow a priori stratification of patients in clinical trials and will help to tailor treatment to patients. Full Text | PDF
Haematological cancer: Prophylactic platelet transfusion is frequently not necessary Charles A. Schiffer Published online: 02 July 2013 p431 | doi:10.1038/nrclinonc.2013.113 A randomized trial compared prophylactic platelet transfusion with transfusion given when bleeding occurred. Decreased platelet usage was noted in the therapeutic transfusion group with a very low incidence of significant bleeding in recipients of autologous transplants. This finding indicates that a 'no-prophylaxis' approach is acceptable in such patients. However, prophylactic platelet transfusion should continue to be the standard in leukaemia patients receiving induction chemotherapy. Full Text | PDF
Targeted therapies: Any surprises from selective oestrogen-receptor modulators? V. Craig Jordan Published online: 11 June 2013 p432 | doi:10.1038/nrclinonc.2013.94 The marriage of medicinal chemistry, molecular biology and medicine is perhaps best exemplified by the evolution of selective oestrogen-receptor modulators (SERMs). Translational studies might be useful for predicting the myriad clinical responses to SERMs, contributing to improvements in women's health. Full Text | PDF
Epidemiology: Biorepositories for cancer research in developing countries Sandipan Ray, Aliasgar Moiyadi & Sanjeeva Srivastava Published online: 09 July 2013 p434 | doi:10.1038/nrclinonc.2013.119 Well-documented biorepositories are essential for cancer research. Currently, major biobanks are located in the developed world, which represents the minority global population; however, countries with low-resource settings contribute more than 50% of the global cancer burden. Therefore, there is an urgent need to establish next-generation biorepositories in developing countries. Full Text | PDF
REVIEWS		Top
Biopsies: next-generation biospecimens for tailoring therapy Mark Basik, Adriana Aguilar-Mahecha, Caroline Rousseau, Zuanel Diaz, Sabine Tejpar, Alan Spatz, Celia M. T. Greenwood & Gerald Batist Published online: 25 June 2013 p437 | doi:10.1038/nrclinonc.2013.101 Insights into tumour biology require biospecimens from the primary tumour and those that reflect the patient's disease in specific contexts. Tumour samples must be representative, viable, and adequate both in quantity and quality for subsequent molecular applications. This Review article outlines the existing procedures for sample procurement and processing of next-generation biospecimens, and highlights the issues involved in this endeavour. Abstract | Full Text | PDF
Chemotherapy dosing in overweight and obese patients with cancer Gary H. Lyman & Alex Sparreboom Published online: 16 July 2013 p451 | doi:10.1038/nrclinonc.2013.108 Evidence indicates that reductions in recommended doses of chemotherapy often occur among obese patients with cancer. ASCO guidelines recommend that chemotherapy dosing in obese patients should be calculated based on actual weight, rather than the current practice based on estimation of body surface area. In this Review, chemotherapy dosing in this population is discussed along with how future research could lead to a more-personalized approach. Abstract | Full Text | PDF
Minimal residual disease in acute myeloid leukaemia Christopher S. Hourigan & Judith E. Karp Published online: 25 June 2013 p460 | doi:10.1038/nrclinonc.2013.100 Definition of complete remission in patients with acute myeloid leukaemia (AML) represents a highly heterogeneous state associated with diverse clinical outcomes. The use of minimal residual disease (MRD) as a response criterion allows efficacy assessment of AML therapy. The authors review the characteristics and challenges of the modalities used to detect MRD and outline opportunities to improve clinical use of MRD measurements. Abstract | Full Text | PDF
Liquid biopsy: monitoring cancer-genetics in the blood Emily Crowley, Federica Di Nicolantonio, Fotios Loupakis & Alberto Bardelli Published online: 09 July 2013 p472 | doi:10.1038/nrclinonc.2013.110 As heterogeneity increasingly needs to be taken into account in the treatment of solid tumours, methods to detect genetic variation have come to the fore. One method that might have considerable clinical utility is the detection of variations in circulating-free DNA. This Review outlines the possibilities and challenges that this technique offers in terms of predictive and prognostic markers, as well as in the detection of therapy resistance. Abstract | Full Text | PDF
CORRESPONDENCE		Top
PTSD—more complicated on second look Richard Fielding & Wendy W. T. Lam Published online: 18 June 2013 p484 | doi:10.1038/nrclinonc.2013.49-c1 Full Text | PDF
Deconstructing the complexity of PTSD in cancer Oxana Palesh & Cheryl Koopman Published online: 18 June 2013 p484 | doi:10.1038/nrclinonc.2013.49-c2 Full Text | PDF
Advertisement
Nature Outlook Leukaemia While survival rates for some types of leukaemia have improved dramatically, this family of blood cancers remains a potentially fatal disease. Research in epigenetics, immunotherapy, and cell transplants offers hope.  Access the Outlook free online for six months.  Produced with support from: Novartis Oncology, Baxter International, Onconova Therapeutics
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.